A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naive Adult Patients With ALK-activated Non-small Cell Lung Cancer

Trial Profile

A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naive Adult Patients With ALK-activated Non-small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ASCEND III
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2018 This trial has been completed in Belgium (end date: 2018-01-22)
    • 23 Feb 2018 The trial has been completed in Sweden according to European Clinical Trials Database record.
    • 15 Feb 2018 The trial has been completed in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top